Repurposing nuclear-penetrating autoantibodies from lupus and scleroderma patients as potent, safe inhibitors of pathogenic NETosis.
Designing synthetic antigens that reprogram allergic immune memory toward durable, healthy responses — moving precision allergy vaccines toward the clinic.
Developing novel multivalent small molecules that selectively silence or eliminate the autoantibody-producing B cells driving autoimmune disease.
Characterizing a newly discovered IgE receptor to develop it into a drug that clears circulating IgE and treats allergic diseases.
Building the largest cerebrospinal fluid immune profile dataset in pediatric autoimmune neurological diseases to enable faster, more accurate diagnosis of MS and related conditions.
Building a CHO cell surface display library of all human proteins to enable comprehensive, high-throughput autoantibody profiling across autoimmune diseases and vaccine responses.
Developing VCAM-1-targeted lipid nanoparticles delivering IL-10 mRNA to reduce neuroinflammation and improve outcomes after intracerebral hemorrhage.
Profiling deep immune changes before AAV relapse to identify predictive biomarkers and therapeutic targets for this difficult-to-manage autoimmune vasculitis.
Developing CART4-34, a novel CAR T cell therapy that selectively eliminates IGHV4-34+ pathogenic B cells in lupus while sparing healthy B cells and avoiding broad immunosuppression.
Building a spatial single-cell atlas of healthy and diseased human kidneys to redefine immune-mediated kidney disease and identify precision diagnostic and therapeutic targets.
